Anifrolumab is indicated for:
Population group: both men and women, only adults (18 years old or older)
Anifrolumab is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite standard therapy.
For this indication, competent medicine agencies globally authorize below treatments (click for details):